-1753360571959.webp&w=3840&q=75)
2025 NOSCM | Immunotherapy in First Line Metastatic Setting
Overview
Dr. Eric Singhi reviewed immunotherapy in first-line metastatic settings, noting 30% five-year survival for PDL1 high patients.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Eric K. Singhi, MD
Date of Release
July 24th, 2025
-1755988066641.webp&w=3840&q=75)
-1755987918967.webp&w=3840&q=75)